{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:14:01Z","timestamp":1790428441646,"version":"4.1.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inhibitors of the mammalian target of rapamycin (mTOR) are currently in clinical trials for the treatment of breast cancer. The mechanisms through which mTOR are activated in breast cancer and the relationship of mTOR activation to steroid hormones, such as estrogen, that are known to influence breast cancer pathogenesis, are not yet understood. Using MCF-7 cells as a model, we found that 17-\u03b2 estradiol (E2) rapidly increased the phosphorylation of downstream targets of mTOR: p70 ribosomal protein S6 kinase, ribosomal protein S6, and eukaryotic initiation factor 4E-binding protein 1. The phosphoinositide-3-kinase inhibitor, wortmannin, and the mTOR inhibitor, rapamycin, blocked E2-induced activation of p70 ribosomal protein S6 kinase. We hypothesized that tuberin and the small GTPase Ras homologue enriched in brain (Rheb), regulators of the mTOR pathway, mediate E2-induced activation of mTOR. Consistent with this hypothesis, E2 rapidly (within 5 minutes) stimulated tuberin phosphorylation at T1462, a site at which Akt phosphorylates and inactivates tuberin. E2 also rapidly decreased the inactive, GDP-bound form of Rheb. Finally, we found that small interfering RNA down-regulation of endogenous Rheb blocked the E2-stimulated proliferation of MCF-7 cells, demonstrating that Rheb is a key determinant of E2-dependent cell growth. Taken together, these data reveal that the TSC\/Rheb\/mTOR pathway plays a critical role in the regulation of E2-induced proliferation, and highlight Rheb as a novel molecular target for breast cancer therapy. (Cancer Res 2006; 66(19): 9461-6)<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-1895","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T15:44:22Z","timestamp":1159890262000},"page":"9461-9466","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Estrogen-Induced Activation of Mammalian Target of Rapamycin Is Mediated via Tuberin and the Small GTPase Ras Homologue Enriched in Brain"],"prefix":"10.1158","volume":"66","author":[{"given":"Jane","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Petri","family":"Henske","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,10,3]]},"reference":[{"key":"2022061622272099700_B1","doi-asserted-by":"crossref","unstructured":"Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene\u20082005; 24: 7475\u201381.","DOI":"10.1038\/sj.onc.1209090"},{"key":"2022061622272099700_B2","doi-asserted-by":"crossref","unstructured":"Choo AY, Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell\u20082006; 9: 77\u20139.","DOI":"10.1016\/j.ccr.2006.01.021"},{"key":"2022061622272099700_B3","doi-asserted-by":"crossref","unstructured":"Sarbassov dos D, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol\u20082005; 17: 596\u2013603.","DOI":"10.1016\/j.ceb.2005.09.009"},{"key":"2022061622272099700_B4","doi-asserted-by":"crossref","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell\u20082006; 124: 471\u201384.","DOI":"10.1016\/j.cell.2006.01.016"},{"key":"2022061622272099700_B5","doi-asserted-by":"crossref","unstructured":"Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol\u20082006; 19: 238\u201345.","DOI":"10.1038\/modpathol.3800525"},{"key":"2022061622272099700_B6","doi-asserted-by":"crossref","unstructured":"Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol\u20082005; 23: 5314\u201322.","DOI":"10.1200\/JCO.2005.66.130"},{"key":"2022061622272099700_B7","doi-asserted-by":"crossref","unstructured":"Johnston SR. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor\/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res\u20082006; 12: 1061\u20138s.","DOI":"10.1158\/1078-0432.CCR-05-2125"},{"key":"2022061622272099700_B8","doi-asserted-by":"crossref","unstructured":"Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer\u20082003; 4: 126\u201337.","DOI":"10.3816\/CBC.2003.n.018"},{"key":"2022061622272099700_B9","doi-asserted-by":"crossref","unstructured":"Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem\u20082003; 278: 32493\u20136.","DOI":"10.1074\/jbc.C300226200"},{"key":"2022061622272099700_B10","doi-asserted-by":"crossref","unstructured":"Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell\u20082003; 11: 1457\u201366.","DOI":"10.1016\/S1097-2765(03)00220-X"},{"key":"2022061622272099700_B11","doi-asserted-by":"crossref","unstructured":"Tee AR, Anjum R, Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase\/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem\u20082003; 278: 37288\u201396.","DOI":"10.1074\/jbc.M303257200"},{"key":"2022061622272099700_B12","doi-asserted-by":"crossref","unstructured":"Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev\u20082003; 17: 1829\u201334.","DOI":"10.1101\/gad.1110003"},{"key":"2022061622272099700_B13","doi-asserted-by":"crossref","unstructured":"Saucedo LJ, Gao X, Chiarelli DA, et al. Rheb promotes cell growth as a component of the insulin\/TOR signalling network. Nat Cell Biol\u20082003; 5: 566\u201371.","DOI":"10.1038\/ncb996"},{"key":"2022061622272099700_B14","doi-asserted-by":"crossref","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol\u20082003; 13: 1259\u201368.","DOI":"10.1016\/S0960-9822(03)00506-2"},{"key":"2022061622272099700_B15","doi-asserted-by":"crossref","unstructured":"Zhang Y, Gao X, Saucedo LJ, et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol\u20082003; 5: 578\u201381.","DOI":"10.1038\/ncb999"},{"key":"2022061622272099700_B16","doi-asserted-by":"crossref","unstructured":"Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-kinase\/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem\u20082002; 277: 35364\u201370.","DOI":"10.1074\/jbc.M205838200"},{"key":"2022061622272099700_B17","doi-asserted-by":"crossref","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol\u20082002; 4: 648\u201357.","DOI":"10.1038\/ncb839"},{"key":"2022061622272099700_B18","doi-asserted-by":"crossref","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell\u20082002; 10: 151\u201362.","DOI":"10.1016\/S1097-2765(02)00568-3"},{"key":"2022061622272099700_B19","doi-asserted-by":"crossref","unstructured":"Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol\u20082002; 4: 658\u201365.","DOI":"10.1038\/ncb840"},{"key":"2022061622272099700_B20","doi-asserted-by":"crossref","unstructured":"Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A\u20082004; 101: 13489\u201394.","DOI":"10.1073\/pnas.0405659101"},{"key":"2022061622272099700_B21","doi-asserted-by":"crossref","unstructured":"Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell\u20082005; 121: 179\u201393.","DOI":"10.1016\/j.cell.2005.02.031"},{"key":"2022061622272099700_B22","doi-asserted-by":"crossref","unstructured":"Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res\u20082005; 11: 5319\u201328.","DOI":"10.1158\/1078-0432.CCR-04-2402"},{"key":"2022061622272099700_B23","doi-asserted-by":"crossref","unstructured":"Evinger AJ 3rd, Levin ER. Requirements for estrogen receptor \u03b1 membrane localization and function. Steroids\u20082005; 70: 361\u20133.","DOI":"10.1016\/j.steroids.2005.02.015"},{"key":"2022061622272099700_B24","doi-asserted-by":"crossref","unstructured":"Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell\u20082001; 104: 719\u201330.","DOI":"10.1016\/S0092-8674(02)08100-X"},{"key":"2022061622272099700_B25","doi-asserted-by":"crossref","unstructured":"Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem\u20082002; 277: 50768\u201375.","DOI":"10.1074\/jbc.M210106200"},{"key":"2022061622272099700_B26","doi-asserted-by":"crossref","unstructured":"Castoria G, Migliaccio A, Bilancio A, et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J\u20082001; 20: 6050\u20139.","DOI":"10.1093\/emboj\/20.21.6050"},{"key":"2022061622272099700_B27","doi-asserted-by":"crossref","unstructured":"Duan R, Xie W, Li X, McDougal A, Safe S. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem Biophys Res Commun\u20082002; 294: 384\u201394.","DOI":"10.1016\/S0006-291X(02)00499-0"},{"key":"2022061622272099700_B28","doi-asserted-by":"crossref","unstructured":"Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature\u20082000; 407: 538\u201341.","DOI":"10.1038\/35035131"},{"key":"2022061622272099700_B29","doi-asserted-by":"crossref","unstructured":"Finlay GA, Hunter DS, Walker CL, Paulson KE, Fanburg BL. Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression. Am J Physiol Cell Physiol\u20082003; 285: C409\u201318.","DOI":"10.1152\/ajpcell.00482.2002"},{"key":"2022061622272099700_B30","doi-asserted-by":"crossref","unstructured":"Flores-Delgado G, Anderson KD, Warburton D. Nongenomic estrogen action regulates tyrosine phosphatase activity and tuberin stability. Mol Cell Endocrinol\u20082003; 199: 143\u201351.","DOI":"10.1016\/S0303-7207(02)00288-5"},{"key":"2022061622272099700_B31","doi-asserted-by":"crossref","unstructured":"Scheele JS, Rhee JM, Boss GR. Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc Natl Acad Sci U S A\u20081995; 92: 1097\u2013100.","DOI":"10.1073\/pnas.92.4.1097"},{"key":"2022061622272099700_B32","doi-asserted-by":"crossref","unstructured":"Karbowniczek M, Cash T, Cheung M, et al. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem\u20082004; 279: 29930\u20137.","DOI":"10.1074\/jbc.M402591200"},{"key":"2022061622272099700_B33","doi-asserted-by":"crossref","unstructured":"Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet\u20082005; 37: 19\u201324.","DOI":"10.1038\/ng1494"},{"key":"2022061622272099700_B34","doi-asserted-by":"crossref","unstructured":"Clark GJ, Kinch MS, Rogers-Graham K, et al. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem\u20081997; 272: 10608\u201315.","DOI":"10.1074\/jbc.272.16.10608"},{"key":"2022061622272099700_B35","doi-asserted-by":"crossref","unstructured":"Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol\u20082006; 102: 292\u20139.","DOI":"10.1016\/j.ygyno.2005.12.019"},{"key":"2022061622272099700_B36","doi-asserted-by":"crossref","unstructured":"Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol\u20082005; 25: 7917\u201325.","DOI":"10.1128\/MCB.25.17.7917-7925.2005"},{"key":"2022061622272099700_B37","doi-asserted-by":"crossref","unstructured":"Kirkegaard T, Witton CJ, McGlynn LM, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol\u20082005; 207: 139\u201346.","DOI":"10.1002\/path.1829"},{"key":"2022061622272099700_B38","doi-asserted-by":"crossref","unstructured":"Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol\u20082004; 166: 213\u201323.","DOI":"10.1083\/jcb.200403069"},{"key":"2022061622272099700_B39","doi-asserted-by":"crossref","unstructured":"Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol\u20082004; 167: 399\u2013403.","DOI":"10.1083\/jcb.200408161"},{"key":"2022061622272099700_B40","doi-asserted-by":"crossref","unstructured":"Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol\u20082004; 14: 1650\u20136.","DOI":"10.1016\/j.cub.2004.08.026"},{"key":"2022061622272099700_B41","doi-asserted-by":"crossref","unstructured":"Jiang WG, Sampson J, Martin TA, et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer\u20082005; 41: 1628\u201336.","DOI":"10.1016\/j.ejca.2005.03.023"},{"key":"2022061622272099700_B42","doi-asserted-by":"crossref","unstructured":"Liu H, Radisky DC, Nelson CM, et al. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A\u20082006; 103: 4134\u20139.","DOI":"10.1073\/pnas.0511342103"},{"key":"2022061622272099700_B43","doi-asserted-by":"crossref","unstructured":"Yue W, Wang J, Li Y, Fan P, Santen RJ. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer\u20082005; 117: 746\u201354.","DOI":"10.1002\/ijc.21222"},{"key":"2022061622272099700_B44","doi-asserted-by":"crossref","unstructured":"deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res\u20082004; 10: 8059\u201367.","DOI":"10.1158\/1078-0432.CCR-04-0035"},{"key":"2022061622272099700_B45","doi-asserted-by":"crossref","unstructured":"Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A\u20082000; 97: 6085\u201390.","DOI":"10.1073\/pnas.97.11.6085"},{"key":"2022061622272099700_B46","doi-asserted-by":"crossref","unstructured":"Sato T, Seyama K, Fujii H, et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet\u20082002; 47: 20\u20138.","DOI":"10.1007\/s10038-002-8651-8"},{"key":"2022061622272099700_B47","unstructured":"Govindarajan B, Mizesko MC, Miller MS, et al. Tuberous sclerosis-associated neoplasms express activated p42\/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin Cancer Res\u20082003; 9: 3469\u201375."},{"key":"2022061622272099700_B48","doi-asserted-by":"crossref","unstructured":"Han S, Santos TM, Puga A, et al. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res\u20082004; 64: 812\u20136.","DOI":"10.1158\/0008-5472.CAN-03-3277"},{"key":"2022061622272099700_B49","doi-asserted-by":"crossref","unstructured":"Henry KW, Yuan X, Koszewski NJ, et al. Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J Biol Chem\u20081998; 273: 20535\u20139.","DOI":"10.1074\/jbc.273.32.20535"},{"key":"2022061622272099700_B50","doi-asserted-by":"crossref","unstructured":"Lou D, Griffith N, Noonan DJ. The tuberous sclerosis 2 gene product can localize to nuclei in a phosphorylation-dependent manner. Mol Cell Biol Res Commun\u20082001; 4: 374\u201380.","DOI":"10.1006\/mcbr.2001.0307"},{"key":"2022061622272099700_B51","doi-asserted-by":"crossref","unstructured":"Noonan DJ, Lou D, Griffith N, Vanaman TC. A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. Arch Biochem Biophys\u20082002; 398: 132\u201340.","DOI":"10.1006\/abbi.2001.2682"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/19\/9461\/2554002\/9461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/19\/9461\/2554002\/9461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:33:13Z","timestamp":1655429593000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/19\/9461\/526194\/Estrogen-Induced-Activation-of-Mammalian-Target-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,1]]},"references-count":51,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2006,10,3]]},"published-print":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-1895","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,1]]}}}